Weak D Testing is not Required for D- Patients With C-E- Phenotype
| Autor: | Hwan Tae Lee, Sejong Chun, HongBi Yu, Ji Young Seo, Sooin Choi, Duck Cho |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Test strategy
Genotype Cost effectiveness D typing Clinical Biochemistry 030204 cardiovascular system & hematology Tertiary Care Centers 03 medical and health sciences 0302 clinical medicine Humans Testing time RHD genotyping Mathematics Retrospective Studies Antihuman globulin Rh-Hr Blood-Group System business.industry Transfusion Medicine Biochemistry (medical) General Medicine Algorithm Phenotype Blood Grouping and Crossmatching Weak D testing 030220 oncology & carcinogenesis C−E− phenotype RhD blood type Original Article Nuclear medicine business Algorithms |
| Zdroj: | Annals of Laboratory Medicine |
| ISSN: | 2234-3814 |
| Popis: | BACKGROUND Although testing to detect weak D antigens using the antihuman globulin reagent is not required for D- patients in many countries, it is routinely performed in Korea. However, weak D testing can be omitted in D- patients with a C-E- phenotype as this indicates complete deletion of the RHD gene, except in rare cases. We designed a new algorithm for weak D testing, which consisted of RhCE phenotyping followed by weak D testing in C+ or E+ samples, and compared it with the current algorithm with respect to time and cost-effectiveness. METHODS In this retrospective study, 74,889 test results from January to July 2017 in a tertiary hospital in Korea were analyzed. Agreement between the current and proposed algorithms was evaluated, and total number of tests, time required for testing, and test costs were compared. With both algorithms, RHD genotyping was conducted for samples that were C+ or E+ and negative for weak D testing. RESULTS The algorithms showed perfect agreement (agreement=100%; κ=1.00). By applying the proposed algorithm, 29.56% (115/389 tests/yr) of tests could be omitted, time required for testing could be reduced by 36% (8,672/24,084 min/yr), and the test cost could be reduced by 16.53% (536.11/3,241.08 USD/yr). CONCLUSIONS Our algorithm omitting weak D testing in D- patients with C-E- phenotype may be a cost-effective testing strategy in Korea. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|